SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 68 filers reported holding SYROS PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $202,000 | -66.9% | 183,253 | +1.5% | 0.00% | – |
| Q4 2021 | $611,000 | -39.4% | 180,588 | -9.1% | 0.00% | – |
| Q3 2021 | $1,009,000 | +2.5% | 198,578 | +10.0% | 0.00% | – |
| Q2 2021 | $984,000 | -10.2% | 180,514 | +23.1% | 0.00% | – |
| Q1 2021 | $1,096,000 | -30.0% | 146,613 | +1.5% | 0.00% | -100.0% |
| Q4 2020 | $1,566,000 | -2.2% | 144,412 | -20.3% | 0.00% | 0.0% |
| Q3 2020 | $1,602,000 | -26.1% | 181,155 | -10.9% | 0.00% | 0.0% |
| Q2 2020 | $2,167,000 | +163.6% | 203,292 | +46.6% | 0.00% | – |
| Q1 2020 | $822,000 | -15.4% | 138,629 | -1.4% | 0.00% | – |
| Q4 2019 | $972,000 | -13.0% | 140,627 | +30.6% | 0.00% | – |
| Q3 2019 | $1,117,000 | +7.7% | 107,639 | -3.9% | 0.00% | – |
| Q2 2019 | $1,037,000 | – | 112,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
| Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
| Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
| Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
| EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
| Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
| Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
| Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
| Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |